Jun 26, 2018   SOURCE: PR NewsWire

Autoinjectors Market, 2030

DUBLIN, June 26, 2018 /PRNewswire/ --

The "Global Autoinjectors Market (2nd Edition), 2018-2030" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The Global Autoinjectors Market (2nd Edition), 2018-2030' report provides a comprehensive analysis of the current state of the autoinjectors market and the likely future evolution of these devices over the next decade. The study presents an in-depth analysis of a diverse set of companies that are engaged in this domain across different regions of the globe.

Over the years, the self-injection devices market has grown into a promising segment of the pharmaceutical industry. The domain is presently characterized by the presence of advanced technology platforms and innovative devices, offering a variety of user-friendly drug delivery solutions.

One of the major driving forces behind the growth in this field is the rising incidence of chronic clinical conditions, such as rheumatoid arthritis, multiple sclerosis and diabetes. Although various pharmacological interventions are available for the treatment of these conditions, they require parenteral administration, frequent hospital visits, and are associated with multiple concerns, such as dosing and medication errors, risk of microbial contamination and needlestick injuries.

However, therapies developed in combination with self-administration enabling devices have witnessed high adoption rates and have actually resulted in marked improvements in adherence to prescribed therapeutic regimens. In addition, such devices have been widely utilized in the treatment of emergency conditions such as anaphylaxis and other allergic disorders.

Amongst other elements, the report includes:

    --  A review of the overall landscape of the autoinjectors market,
        highlighting the contributions of industry players and the key device
        specifications, including the primary drug container used, its volume,
        usability of the device, route of administration, indication and
        targeted drugs.
    --  An in-depth patent analysis to provide an overview on how the industry
        has evolved from the R&D perspective. For this analysis, we looked at
        the patents that have been published since 2013. The analysis also
        highlights key information associated with these patents, such as patent
        type, regional distribution, CPC classification, IP litigations,
        emerging areas and leading industry players.
    --  A comprehensive product competitiveness analysis of disposable and
        reusable autoinjectors taking into consideration the supplier power
        (based on size of employee base) and product specifications, such as
        route of administration, primary drug container used, mechanism of
        operation, dosage type and user friendliness.
    --  Comprehensive profiles of autoinjector manufacturers that have more than
        three devices in their respective product portfolios; each profile
        features an overview of the company, its financial information (if
        available), information on its product portfolio, autoinjector device
        specifications, collaborations, recent developments and a comprehensive
        future outlook. Additionally, the report includes brief profiles of
        emerging players that have been established in the past decade.
    --  Detailed case studies on the most commonly targeted indications,
        covering history of development and detailed description of the approved
        autoinjector products, along with their respective mechanisms of action
        and historical sales records. In addition, we have listed all the drugs
        that are currently being delivered through autoinjectors.
    --  A list of marketed and pipeline candidates that are likely to be
        developed in combination with autoinjectors in the near future; the
        candidate drugs / therapies were selected based on various parameters,
        such as their current route of administration, target therapeutic
        indication and dosage. For the purpose of this analysis, we collated a
        list of over 100 top-selling marketed drugs, which were initially
        screened on the basis of route of administration (subcutaneous /
        intramuscular). Additionally, we reviewed over 900 clinical trials and
        compiled a list of pipeline molecules that are being investigated for
        delivery via the aforementioned routes. The likelihood of delivery via
        autoinjector device in the future was estimated by assigning a specific
        score (weight) to each parameter.
    --  A SWOT analysis capturing the key parameters and trends that are likely
        to influence the future of autoinjectors market.

Key Topics Covered:

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Drug Delivery Systems
3.3. Conventional Parenteral Delivery
3.4. Needlestick Injuries
3.5. Self-Administration: An Emerging Trend
3.6. Safety Options in Self-Injectors
3.7 Types of Self-Injection Devices
3.8. Autoinjectors: An Important Class of Self-Injection Devices
3.9. Concluding Remarks

4. PRIMARY DRUG CONTAINERS IN AUTOINJECTORS
4.1. Chapter Overview
4.2. Introduction to Primary Drug Containers
4.3 Types of Primary Drug Containers

5. AUTOINJECTORS: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Autoinjectors: Overall Market Overview
5.3. Approved Combination Products: Overall Market Overview
5.4. Pipeline Combination Products: Overall Market Overview

6. PATENT ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Autoinjectors: Patent Analysis
6.4. Autoinjectors: Patent Benchmarking Analysis
6.5. Autoinjectors: Patent Valuation Analysis
6.6. Leading Patents Based on Number of Citations

7. CASE STUDIES
7.1. Chapter Overview
7.2. Marketed / Pipeline Drugs Being Evaluated with Autoinjectors
7.3 Case Study I: Anaphylaxis
7.4. Case Study II: Multiple Sclerosis
7.5. Case Study III: Migraine
7.6. Case Study IV: Rheumatoid Arthritis

8. LIKELY DRUG CANDIDATES FOR DELIVERY VIA AUTOINJECTORS
8.1. Chapter Overview
8.2. Marketed Molecules
8.3. Pipeline Molecules

9. KEY PLAYERS
9.1. Chapter Overview
9.2. Antares Pharma
9.3. Company Overview
9.4. DALI Medical Devices
9.5. Elcam Medical (E3D Elcam Drug Delivery Devices)
9.6. Jiangsu Delfu Medical Devices
9.7. Meridian Medical Technologies
9.8. Owen Mumford
9.9. SHL Group
9.10. Union Medico
9.11. Ypsomed

10. EMERGING PLAYERS
10.1. Chapter Overview
10.2. AktiVax
10.3. Future Injection Technologies
10.4. Impax Laboratories (Amedra Pharmaceuticals)
10.5. Kalo Pharma
10.6. MiniEpi
10.7. Nemera
10.8. Nuance Designs
10.9. Oval Medical Technologies
10.10. Windgap Medical
10.11. Xeris Pharmaceuticals
10.12. Zion Clinical Pharmacy

11. SWOT ANALYSIS
11.1. Chapter Overview
11.2. Strengths
11.3. Weaknesses
11.4. Opportunities
11.5. Threats

12. MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Global Autoinjectors Market
12.3. Autoinjectors Market for Anaphylaxis
12.4. Autoinjectors Market for Multiple Sclerosis
12.5. Autoinjectors Market for Rheumatoid Arthritis
12.6. Autoinjectors Market for Migraine
12.7. Autoinjectors Market for Diabetes
12.8. Autoinjectors Market for Other Indications

13. CONCLUSION
13.1. Rising Incidence of Chronic Illnesses has Augmented the Demand for Devices that Enable Self-Medication
13.2. Given their Numerous Benefits, Autoinjectors have Emerged as Potent Drug Delivery Tools
13.3. Several Combination Products have Already been Approved and Many are Under Development
13.4. Majority of the Available Products are Disposable; However, Reusable Devices are Gradually Gaining Popularity
13.5. Although the Market is Led by the Well-Established Players, Start-Ups Continue to Spearhead the Innovation in this Field
13.6. Led by Several Growth Opportunities, the Market is Expected to Evolve at a Steady Pace over the Coming Decade

14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. PHC
14.3. Elcam Medical
14.4. DALI Medical Devices

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

    --  AbbVie
    --  Ablynx
    --  Acceleron Pharma
    --  Allergan
    --  Acuitas Therapeutics
    --  Aesica Pharmaceuticals
    --  Laboratoire AGUETTANT
    --  AktiVax
    --  Alexion Pharmaceuticals
    --  ALK-Abell A/S
    --  Allergy Therapeutics
    --  Alnylam Pharmaceuticals
    --  Alphamab Jilin
    --  Alvogen
    --  AMAG Pharmaceuticals
    --  Amedra Pharmaceuticals
    --  Amgen
    --  Amneal Pharmaceuticals
    --  Amylin Pharmaceuticals
    --  Androsystems
    --  AnGes
    --  Antares Pharma
    --  Antaros Medical
    --  Aptar Pharma
    --  Arrowhead Pharmaceuticals
    --  Arte
    --  Arteaus Therapeutics
    --  Asahi Kasei Pharma
    --  Ascendis Pharma
    --  Astellas Pharma
    --  AstraZeneca
    --  Axon Neuroscience
    --  Bay City Capital
    --  Bayer
    --  BD Medical
    --  Beijing Dongfang Biotech
    --  Bespak
    --  Betta Pharmaceuticals
    --  Biocad
    --  Biocon
    --  Biogen
    --  BioGenCell
    --  BioGene Pharmaceutical
    --  BioLineRx
    --  BioMarin Pharmaceutical
    --  Bioprojet Pharma
    --  Boehringer Ingelheim
    --  Boston Pharmaceuticals
    --  Bristol-Myers Squibb
    --  Caladrius Biosciences
    --  Cambridge Consultants
    --  Celgene
    --  Celltrion Healthcare
    --  ChemProtect SK
    --  Chugai Pharmaceutical
    --  CinnaGen
    --  Connected Health Services
    --  Consort Medical
    --  Corvidia Therapeutics
    --  Creare
    --  Crossject
    --  CSL Behring
    --  CuraVac
    --  CytoDyn
    --  Daikyo Seiko
    --  DALI Medical Devices
    --  Deerfield Management
    --  DiaMedica Therapeutics
    --  Disetronic Holding
    --  Dr. Reddy's Laboratory
    --  Eiger BioPharmaceuticals
    --  Eisai
    --  Elcam Medical
    --  Elli Lilly
    --  EMD Serono
    --  Emergent BioSolutions
    --  Ferring Pharmaceuticals
    --  Future Injection Technologies
    --  Galderma R&D
    --  Genentech
    --  Gerresheimer
    --  Gilead Sciences
    --  GlaxoSmithKline
    --  Globe Medical Tech
    --  HAL Allergy Group
    --  Hanmi Pharmaceuticals
    --  Haselmeier
    --  Hoffmann-La Roche
    --  Hospira
    --  Idera Pharmaceuticals
    --  Immune Response BioPharma
    --  Immunex
    --  Impax Laboratories
    --  Injectech
    --  Inmunotek
    --  Innovent Biologics
    --  Ionis Pharmaceuticals
    --  Ipsen
    --  Janssen Biotech
    --  JCR Pharmaceuticals
    --  Jerini
    --  Jiangsu Delfu Medical Device
    --  Kalo
    --  Kang Stem Biotech
    --  KeyBioscience
    --  King Pharmaceuticals
    --  Kisling
    --  Kyowa Hakko Kirin
    --  LEO Pharma
    --  Lineage Therapeutics
    --  LyoGo
    --  M3 Biotechnology
    --  Meda Pharmaceuticals
    --  Medac Pharma
    --  Medeca Pharma
    --  Medicom Innovation Partner
    --  Medimop Medical Projects
    --  MedPro Group
    --  Merck
    --  Meridian Medical Technologies
    --  Mrieux Dveloppement
    --  MGlas
    --  MiniEpi
    --  Momenta Pharmaceuticals
    --  Mylan
    --  Nemera
    --  NGM Biopharmaceuticals
    --  Nipro PharmaPackaging
    --  Nordic Bioscience
    --  Novartis
    --  Novo Nordisk
    --  Nuance Designs
    --  Ompi - Stevanato Group
    --  OneWorld DMG
    --  OPKO Biologics
    --  Otsuka Pharmaceutical
    --  Oval Medical Technologies
    --  Owen Mumford
    --  PA Consulting Group
    --  Palatin Technologies
    --  Palmetto Partners
    --  Pfizer
    --  PHC
    --  Plas-Tech Engineering
    --  Pluristem Therapeutics
    --  PRA Health Sciences
    --  ProJect Pharmaceutics
    --  Promius Pharma
    --  QuiO
    --  RaviMed
    --  Redmile Group
    --  Regeneron Pharmaceuticals
    --  REMD Biotherapeutics
    --  Revolutions Medical
    --  Rhythm Pharmaceuticals
    --  Roselabs Bioscience
    --  Samsung Bioepis
    --  Sandoz
    --  Sanofi
    --  Santarus
    --  Schott
    --  Schreiner MediPharm
    --  Serina Therapeutics
    --  Shandong Weigao
    --  Shire
    --  SHL Group
    --  SiliCycle
    --  SiO2 Medical Products
    --  SK Chemicals
    --  SKINSORB Cosmetics
    --  SMC
    --  Stealth BioTherapeutics
    --  Sumitomo Dainippon Pharma
    --  Sun Pharmaceutical
    --  Survival Technologies
    --  Synthon Hisapania
    --  TaiMed Biologics
    --  Taisei Kako
    --  Takeda Pharmaceutical
    --  Terumo
    --  Teva Pharmaceutical Industries
    --  The Medical House
    --  The Medicines Company
    --  Thinfilm Electronics
    --  Tolmar
    --  Tonghua Dongbao Pharmaceutical
    --  TSH Biopharm
    --  UCB Biopharma
    --  Ultragenyx Pharmaceutical
    --  Uman Pharma
    --  Unilife
    --  Union Medico
    --  US Medical Instruments
    --  US WorldMeds
    --  Valeant Pharmaceuticals International
    --  Vetter Pharma
    --  ViiV Healthcare
    --  Vitaeris
    --  West Pharmaceutical Services
    --  Wild Basin Investments
    --  Windgap Medical
    --  Xeris Pharmaceuticals
    --  Ypsomed
    --  Zafgen
    --  Zion Clinic Pharmacy

For more information about this report visit https://www.researchandmarkets.com/research/mz9bhl/autoinjectors?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/autoinjectors-market-2030-300672318.html

SOURCE Research and Markets